InVivo Therapeutics Holdings Co (NVIVQ)
Market Cap | 1.15M |
Revenue (ttm) | n/a |
Net Income (ttm) | -9.33M |
Shares Out | 3.11M |
EPS (ttm) | -3.29 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 824 |
Open | 0.330 |
Previous Close | 0.370 |
Day's Range | 0.322 - 0.370 |
52-Week Range | 0.150 - 1.410 |
Beta | n/a |
Analysts | n/a |
Price Target | n/a |
Earnings Date | n/a |
About NVIVQ
InVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States. The company engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant comprise of biocompatible and bioresorbable polymers, which includes Poly lactic-co-glycolic acid, a polymer which is widely used in resorbable sutures and provides the biocompatible support for Neuro-Spinal Scaffold implant; and... [Read more]
Financial Performance
Financial StatementsNews
![](https://cdn.snapi.dev/images/v1/l/j/press7-1789406.jpg)
InVivo Therapeutics Announces Topline Data from Pivotal INSPIRE 2.0 Study in Acute Spinal Cord Injury
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord ...
![](https://cdn.snapi.dev/images/v1/a/z/press6-1578129.jpg)
InVivo Therapeutics Announces Closing of $9 Million Registered Direct and Private Placement Offerings, Priced At-the-Market Under Nasdaq Rules
CAMBRIDGE, Mass--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord i...
![](https://cdn.snapi.dev/images/v1/p/r/press2-1573602.jpg)
InVivo Therapeutics Announces $9 Million Registered Direct and Private Placement Offerings, Priced At-the-Market Under Nasdaq Rules
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord ...
![](https://cdn.snapi.dev/images/v1/s/h/conf4-1537986.jpg)
InVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright 24th Annual Global Investment Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord ...
![](https://cdn.snapi.dev/images/v1/g/d/press20-1450332.jpg)
InVivo Therapeutics Announces Appointment of Heather M. Hamel as Chief Legal Officer and General Counsel
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord ...
![](https://cdn.snapi.dev/images/v1/f/5/press7-1407865.jpg)
InVivo Therapeutics Announces Publication of 12- and 24-month Data for INSPIRE 1.0 Study in Peer-Reviewed Neurosurgery
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced the publication of a peer-reviewed manuscript in Neurosurgery describing the previously disclosed 1...
![](https://cdn.snapi.dev/images/v1/5/c/press20-1400253.jpg)
InVivo Therapeutics Announces Completion of Enrollment for the INSPIRE 2.0 Acute Spinal Cord Injury Study
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord ...
![](https://cdn.snapi.dev/images/v1/g/t/press10-1321776.jpg)
InVivo Therapeutics Announces Reverse Stock Split
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced a 1-for-25 reverse stock split of its common stock and a proportionate reduction in its authorized ...
![](https://cdn.snapi.dev/images/v1/e/v/press15-1174624.jpg)
InVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright BioConnect Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord ...
![](https://cdn.snapi.dev/images/v1/1/x/conf2-1000023.jpg)
InVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright Annual Global Investment Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord ...
![](https://cdn.snapi.dev/images/v1/z/q/press13-997787.jpg)
InVivo Therapeutics Announces 75% Target Enrollment Achieved for the INSPIRE 2.0 Spinal Cord Injury Study
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord ...
InVivo Therapeutics Stock Moves Higher On FDA Acceptance Of Preclinical Module For Neuro-Spinal Implant
The FDA has accepted InVivo Therapeutics Holdings Corp's (NASDAQ: NVIV) preclinical module, which is one of three individual modules required for the Company's humanitarian device exemption (HDE) appl...
![](https://cdn.snapi.dev/images/v1/d/b/press2-904506.jpg)
InVivo Therapeutics Announces FDA Acceptance of Preclinical Module in Support of Company's Complete HDE Submission
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord ...
![](https://cdn.snapi.dev/images/v1/9/t/press18-895119.jpg)
InVivo Therapeutics Urges All Stockholders to Vote at the 2021 Annual Meeting to Be Held on Friday July 16, 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord ...
![](https://cdn.snapi.dev/images/v1/h/p/conf8-721053.jpg)
InVivo Therapeutics Announces Presentation at Upcoming M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord ...
![](https://cdn.snapi.dev/images/v1/v/q/press2-710131.jpg)
InVivo Therapeutics Announces Presentation at Upcoming 2021 H.C. Wainwright Global Life Sciences Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord ...
![](https://cdn.snapi.dev/images/v1/i/c/press20---ojmtpfnp25.jpg)
InVivo Therapeutics Announces Publication in Peer-Reviewed Journal of Neurosurgery: Spine
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced the recent publication of a peer-reviewed manuscript in the Journal of Neurosurgery: Spine describi...
![](https://cdn.snapi.dev/images/v1/s/a/press17---t2nft8xrdk.jpg)
InVivo Therapeutics Announces Closing of $15.0 Million Public Offering
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced the closing of its previously announced public offering of 18,750,000 shares of its common stock (o...
![](https://cdn.snapi.dev/images/v1/l/u/conf2.jpg)
InVivo Therapeutics Announces Presentation at the Upcoming H.C Wainwright Virtual Global Investment Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp.